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Osteoarthritis becomes an affliction for very many people
worldwide at some point in their lives. Although the disease
is not life-threatening it can have, nevertheless, an enor-
mous socioeconomic impact by causing extreme discom-
fort and disability. Osteoarthritis has been known to
mankind since its origins but now, thanks to the bold
approach of surgically replacing dysfunctional joints with
endoprostheses, long-term relief can be provided for many
patients. However, in spite of a substantial research effort,
therapeutic strategies addressed to the underlying causes
are still not in sight. Why?
The term osteoarthritis is applied to a heterogeneous
group of degenerative joint disorders. Some pathogenetic
mechanisms result from mutations in single genes1–4
but the majority of osteoarthritic aetiologies so far remain
elusive. This holds even for the genetic causes. Nature
certainly has taken some risks. The peril is that, some-
times, cartilage is a tissue meant to be permanent, most
prominently so in joint cartilage. However, similar tissues
serve in development, growth and repair of bones and, in
these cases, the physiological destiny of cartilage is to
degenerate and, eventually, to disappear. If the control
mechanisms of cartilage homeostasis confuse the two
situations there will be serious consequences. Is osteo-
arthritis, therefore, nothing but a misguided form of bone
formation?
What are the molecular levers controlling cartilage devel-
opment and differentiation or endochondral ossification?
And what keeps articular cartilage permanent with—
hopefully—minimal changes throughout life? The two ques-
tions seem to be interrelated. They stood at the centre of
interest in a meeting, sponsored by Sulzer Medica, that
took place in Surlej in the Engadine Valley in Switzerland.
Novel and state-of-the-art treatments by orthopaedic sur-
gery of cartilage defects were presented (Jakob et al.). In
addition, a small group of experts in cartilage biology joined
their efforts with a few specialists in tissue engineering to
gain insight from the first, still insecure steps in making new
joint cartilage in vitro and from the fate of the engineeredS1tissue in experimental joint defects. The results are
described in the following articles by Mainil-Varlet et al. and
Weisser et al. What could be suitable cellular sources for
such cartilage and what treatment do such cells need? This
is addressed by the articles of Mastrogiacomo et al.,
Hedbom et al. and Hiraki et al. Why is the graft cartilage
sometimes integrated very well into host tissues but, un-
fortunately, not always? In addition, the formation of
functionally inferior fibrocartilage cannot be prevented
reliably. Why not?
The group has looked at these and related questions
from several angles. The largest volume fraction in carti-
lage is occupied by the extracellular matrix which also
takes over many critical tissue functions. What are the
macromolecular matrix components of skeletal tissues
(Segat et al., Svensson et al.) and how can they be
investigated by novel methods (Calabro et al.)? How is the
extracellular matrix perceived at the cell surface by integrin
matrix receptors (Eble)? Endochondral bone formation is
affected, sometimes severely, by mutations in genes for
matrix macromolecules which can occur naturally in
patients with heritable connective tissue disorders. This is
reviewed by Bateman. Gene alterations can also be intro-
duced experimentally in whole animals. A number of con-
sequences of such manipulations are visited by Aszo´di
et al., Lefebvre et al., So et al., Uusitalo et al., and
Vortkamp which sheds new light on cartilage physiology.
Not only do we learn about the functions of matrix macro-
molecules, but also of intra- and extracellular components
of signalling cascades. Regulatory mechanisms, however,
remain a major domain for cell culture studies where the
consequences of experimental perturbation can be investi-
gated most directly. Examples are given in the articles
by Descalzi-Cancedda et al., Enomoto-lwamoto et al.,
Farjanel et al., Iwamoto et al., Koyano et al., Lefebvre et al.,
Poliard et al., and Shukunami and Hiraki. The complexity of
the regulators (matrix components, extracellular signals,
intracellular cascades) is revealed. There is positive and
negative control of chondrocyte differentiation. It also
becomes apparent that all components act in the context of
each other and this fact severely complicates the interpret-
ation of in vitro studies.
The meeting held in the vicinity of some of the major
peaks of the Alps concluded that there still is a long way
uphill towards the goal of understanding cartilage biology.
The benefits of eventually achieving this goal, however, will
S2 P. Bruckner: Editorialbe rewarding—as is the strenuous effort of reaching the
summit of a tall, snow- and ice-covered mountain.References
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